H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) Ltd on Friday, setting a price target of $78, which is approximately 42.80% above the present share price of $54.62.
Arce expects Arcturus Therapeutics Ltd to post earnings per share (EPS) of -$0.67 for the third quarter of 2020.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Arcturus Therapeutics, with an average price target of $58.25.
The analysts price targets range from a high of $78 to a low of $31.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.65 million and a net profit of -$9.46 million. The company's market cap is $1.12 billion.
According to TipRanks.com, H.C. Wainwright analyst Ed Arce is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 17.7% and a 44.64% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.